

COPY OF PAPERS  
ORIGINALLY FILED

1646  
P#4

TECH CENTER 1600/2900

JAN 17 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Yat Sun Or *et al.*  
U.S. Appl. Serial No.: 09/976,219  
Filing date: October 12, 2001  
Group Art Unit: 1646  
Examiner: TBD  
Title: Cyclosporin Analogs for the Treatment of Autoimmune Diseases

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited today with the United States Postal Service as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, D.C. 20231.

Stacie Capotosto

Date: 12/18/01

INFORMATION DISCLOSURE STATEMENT

Box DD  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir/ Madam:

In accordance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98 in the aforementioned matter, Applicants wish to bring to the Examiner's attention the following references, references AA, BA and BB, cited on the attached Form PTO-1449 (Rev. 2-32):

- 1) U.S. Patent No. 5,525,590 (ref. AA);
- 2) European Patent Application No. 0296122 A2 (ref. BA); and
- 3) European Patent Specification No. 0296122 B1 (ref. BB).


In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed:

- ☒ (1) **within three (3) months of the Filing Date** or before the mailing date of the First Office Action on the merits; or
- ☐ (2) within three months of the mailing date of the PCT International Search Report; or
- ☐ (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$ 180.00, is included herein; or
- ☐ (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form PTO-1449 (Rev. 2-32) be made of record in this application. Copies of these documents (CHECK ONE):

- ☒ are enclosed herewith; or
- ☐ have been cited in an earlier related application, and need not be submitted herein (courtesy copy enclosed).

Respectfully Submitted by,



Sandhya Kalkunte  
Registration No. 46,466

Enanta Pharmaceuticals, Inc.  
Tel: (617) 607-0747  
Fax: (617) 607-0535  
Date: December 18, 2001